Arcato's first product, OraWax, will target orthodontists and their patients as the first effective treatment for oral discomfort caused by braces. Based on intellectual property exclusively licensed to Arcato, OraWax will relieve the irritation and discomfort experienced by orthodontics patients. Current products (e.g., Tylenol or Advil; Orajel or Anbesol) are ineffective at bringing significant relief to brace patients, but medicated OraWax has demonstrated a significant reduction in brace patient discomfort in a controlled clinical study. Arcato will develop future products by expanding on its current proprietary technology platform, as well as aggressively seeking to create or in-license complementary intellectual property.